Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mycophenolate mofetil
Drug ID BADD_D01507
Description Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH).[A180805] This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants.[L7363] It is marketed by Roche Pharmaceuticals and was granted FDA approval for the prophylaxis of transplant rejection in 1995.[A180826] In addition to the above uses, mycophenolate mofetil has also been studied for the treatment of nephritis and other complications of autoimmune diseases. Unlike another immunosuppressant class, the calcineurin inhibitors, MMF generally does not cause nephrotoxicity or fibrosis.[A180799,A180805] Previously, mycophenolic acid (MPA) was administered to individuals with autoimmune diseases beginning in the 1970s, but was discontinued due to gastrointestinal effects and concerns over carcinogenicity.[A180826] The new semi-synthetic 2-morpholinoethyl ester of MPA was synthesized to avoid the gastrointestinal effects associated with the administration of MPA. It demonstrates an increased bioavailability, a higher efficacy, and reduced gastrointestinal effects when compared to MPA.[A180826]
Indications and Usage For the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. Mycophenolate mofetil should be used concomitantly with cyclosporine and corticosteroids.
Marketing Status Prescription; Discontinued
ATC Code L04AA06
DrugBank ID DB00688
KEGG ID D00752
MeSH ID D009173
PubChem ID 5281078
TTD Drug ID D04FBR
NDC Product Code 0781-2067; 0904-7078; 70121-1584; 67877-230; 17478-422; 0093-7334; 71288-803; 70748-262; 70966-0015; 60429-070; 67877-266; 68254-0015; 69238-1595; 68254-2500; 51079-721; 16729-019; 68254-5000; 16714-345; 0378-4472; 65727-005; 17478-957; 66499-0006; 50090-2541; 55154-5382; 64380-725; 68382-669; 55486-1589; 0527-5160; 67877-225; 52972-0037; 72969-053; 78848-004; 0378-2250; 60429-059; 47848-019; 0004-0259; 0904-7074; 50090-4275; 70518-3068; 51079-379; 0004-0260; 0054-0166; 68254-0005; 64380-726; 68254-5003; 70748-186; 71052-317; 70518-2835; 0054-0163; 0004-0261; 70518-2767; 0781-5175; 42023-172; 60687-438; 70771-1084; 67457-386; 60687-494; 71610-033; 46014-1123; 65050-2101; 51927-5125; 66689-307; 16729-094; 55154-6262; 52076-6220
Synonyms Mycophenolic Acid | Mycophenolate Mofetil | Mofetil, Mycophenolate | Mycophenolic Acid Morpholinoethyl Ester | Cellcept | Mycophenolate Sodium | Sodium Mycophenolate | Mycophenolate, Sodium | Myfortic | Mycophenolate Mofetil Hydrochloride | Mofetil Hydrochloride, Mycophenolate | RS 61443 | RS-61443 | RS61443
Chemical Information
Molecular Formula C23H31NO7
CAS Registry Number 128794-94-5
SMILES CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)OCCN3CCOCC3)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bronchopulmonary aspergillosis22.07.08.001; 11.03.01.0020.000853%Not Available
Burning sensation17.02.06.001; 08.01.09.029--Not Available
C-reactive protein increased13.09.01.0070.002616%Not Available
Cachexia16.32.03.011; 14.03.02.001; 08.01.01.009--Not Available
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.001--
Cardiac failure congestive02.05.01.002--Not Available
Cardiac tamponade02.06.01.0010.000341%
Cardiogenic shock24.06.02.006; 02.05.01.0030.000853%Not Available
Cardiomegaly02.04.02.001--Not Available
Cardiomyopathy02.04.01.001--Not Available
Cardiovascular disorder24.03.02.009; 02.01.01.0010.000512%Not Available
Cataract06.06.01.001--
Catatonia19.11.01.001--Not Available
Cellulitis11.02.01.001; 23.09.01.001--Not Available
Central nervous system neoplasm17.20.01.001; 16.30.01.001--Not Available
Cerebellar syndrome17.02.02.0020.001308%Not Available
Cerebral ischaemia17.08.01.005; 24.04.06.003--
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Cervix disorder21.06.01.003--Not Available
Cheilitis07.05.01.001; 23.03.03.025--
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
Chills15.05.03.016; 08.01.09.001--
Cholangitis09.02.01.0020.000512%Not Available
Cholecystitis09.03.01.001--
Cholelithiasis09.03.01.002--Not Available
Cholestasis09.01.01.0010.001308%Not Available
Cleft lip15.11.05.002; 07.05.08.002; 03.11.05.0020.001308%Not Available
Cleft lip and palate07.05.08.003; 03.04.02.0030.003923%Not Available
Cleft palate07.05.08.001; 03.04.02.0010.001308%Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 28 Pages